Cell Therapy in Patients with COVID-19 Using Wharton’s Jelly Mesenchymal Stem Cells: A Phase I Clinical Trial

Scientists assessed the safety and efficacy of injecting intravenous Wharton’s jelly-derived MSCs in patients with COVID-19 as a treatment. Five patients with severe COVID-19 were treated with Wharton’s jelly-derived mesenchymal stem cells.